Overview



As of January 1 2022, Transplant International is no longer published by Wiley.


Current content can be found on the new publisher’s site here: Transplant International | Home (frontierspartnerships.org)

Mission Statement

Transplant International aims to be the premier journal publishing the key basic science and clinical developments in organ replacement medicine, including all aspects of transplantation, organ reconditioning, cell therapy, regenerative medicine, bioengineering and artificial organs.


DEI Statement

At Transplant International , we believe that diversity is the essence of humankind. We value engagement and inclusion at all stages of science communication and dissemination, from the submission of research manuscripts, through the editorial and review process and on to publication. We welcome submissions from applicants of all ethnicities, nationalities, religions, gender identities, sexual orientations or other individual status, and are committed to eliminating the influence of any bias in our processes.

We recognise that this endeavour requires an ongoing commitment; the journal will continually review its practices in this regard and welcomes any feedback from our authors and community. 



Featured

Skip slideshow

Articles

Acknowledgements to reviewers
Free to Read

Acknowledgements to reviewers

  •  2913-2917
  •  30 December 2022
Original Article
Open access

Comparison of pregnancy outcomes in Dutch kidney recipients with and without calcineurin inhibitor exposure: a retrospective study

  •  2669-2679
  •  19 November 2021

Graphical Abstract

Comparison of pregnancy outcomes in Dutch kidney recipients with and without calcineurin inhibitor exposure: a retrospective study Issue 12, 2021

A retrospective study with all Dutch pregnant kidney transplant recipients in 1986–2017, where maternal and foetal pregnancy outcomes were compared between patients using a CNI immunosuppressive regimen and patients, not using CNIs.

Original Article
Free to Read

Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases

  •  2205-2213
  •  18 November 2021

Graphical Abstract

Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases Issue 11, 2021

The majority of colorectal cancer patients receiving a liver transplant will have a relapse. The lung is the most frequent organ of relapse after liver transplantation in these patients. Many of the pulmonary metastases were resected, with 5-year overall survival from metastasectomy of 66.5%.

Original Article
Open access

Autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation

  •  2816-2823
  •  17 November 2021

Graphical Abstract

Autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation Issue 12, 2021

First-in-man trial of adoptive cell therapy with autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation.

More articles

The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.

More articles

Latest news